FY2029 EPS Estimates for XFOR Increased by Analyst

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Equities researchers at Brookline Capital Markets boosted their FY2029 earnings per share estimates for X4 Pharmaceuticals in a research report issued on Thursday, August 6th. Brookline Capital Markets analyst L. Cann now anticipates that the company will earn $0.99 per share for the year, up from their previous forecast of $0.88. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.71) per share.

Other equities analysts also recently issued reports about the stock. Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Wells Fargo & Company assumed coverage on shares of X4 Pharmaceuticals in a research note on Friday, July 10th. They set an “overweight” rating and a $11.00 price objective on the stock. Finally, Leerink Partners began coverage on shares of X4 Pharmaceuticals in a report on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 price objective for the company. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.70.

X4 Pharmaceuticals Stock Up 0.7%

XFOR opened at $4.28 on Monday. The firm’s 50-day simple moving average is $4.03 and its 200-day simple moving average is $3.95. The company has a debt-to-equity ratio of 0.45, a quick ratio of 9.98 and a current ratio of 10.18. X4 Pharmaceuticals has a twelve month low of $1.65 and a twelve month high of $4.83. The firm has a market cap of $403.69 million, a price-to-earnings ratio of -3.57 and a beta of 0.37.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. X4 Pharmaceuticals had a negative return on equity of 64.95% and a negative net margin of 568.80%.The company had revenue of $8.81 million during the quarter, compared to analysts’ expectations of $2.42 million.

Insider Buying and Selling

In other news, CFO David Kirske sold 8,543 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $4.26, for a total transaction of $36,393.18. Following the sale, the chief financial officer owned 167,750 shares in the company, valued at approximately $714,615. This represents a 4.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.13% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in XFOR. Rhumbline Advisers increased its holdings in shares of X4 Pharmaceuticals by 5.4% in the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after purchasing an additional 9,690 shares in the last quarter. Indivisible Partners acquired a new position in X4 Pharmaceuticals during the 4th quarter worth $40,000. Pettinga Financial Advisors LLC acquired a new position in X4 Pharmaceuticals during the 2nd quarter worth $47,000. SummitTX Capital L.P. bought a new position in X4 Pharmaceuticals in the 1st quarter valued at $46,000. Finally, Squarepoint Ops LLC bought a new position in X4 Pharmaceuticals in the 4th quarter valued at $50,000. 72.03% of the stock is owned by institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.